Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AvicannaFRA:0NN +0.65%50 Debt-to-Equity is 0.04 as of Jun. 2026, which is 43% below its 10-year median of 0.07. GuruFocus rates FRA:0NN with a GF Score™ of 50/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Avicanna ranks better than 84.99% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Avicanna's Debt-to-Equity or its related term are showing as below:
FRA:0NN'
s Debt-to-Equity Range Over the Past 10 Years
Min: -15.96 Med: 0.07 Max: 46.06
Current: 0.04
During the past 10 years, the highest Debt-to-Equity Ratio of Avicanna was 46.06. The lowest was -15.96. And the median was 0.07.
FRA:0NN's Debt-to-Equity is ranked better than 84.99% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:0NN: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Avicanna Debt-to-Equity Related Terms
Avicanna Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Avicanna's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avicanna Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avicanna's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Avicanna's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avicanna (FRA:0NN) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avicanna and its competitors. This is 43% below median its historical median of 0.07. According to the industry distribution chart, Avicanna ranks #122 out of 813 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Avicanna's Debt-to-Equity too high?
Avicanna's current Debt-to-Equity of 0.04 is 43% below median its 10-year median of 0.07. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Avicanna's value of 0.04 is 85.2% below this industry median. Based on the distribution chart, Avicanna ranks #122 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Avicanna has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Avicanna's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avicanna ranks #122 out of 813 companies for Debt-to-Equity. This places Avicanna in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Avicanna's value of 0.04 is 85.2% below this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.27, Avicanna has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avicanna's current Debt-to-Equity of 0.04 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avicanna and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avicanna's current Debt-to-Equity is 0.04, which is 43% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avicanna stock overvalued right now?
Avicanna (FRA:0NN) has a current Debt-to-Equity of 0.04. The stock's GF Value™ is €0.15, compared to a current price of €0.08 — trading 48.7% below its estimated fair value. The current Debt-to-Equity is 0.04, which is 43% below median its 10-year median of 0.07 and 85.2% below the Drug Manufacturers industry median of 0.27. Avicanna's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Avicanna (FRA:0NN), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avicanna (FRA:0NN) Overvalued in 2026?
Based on GuruFocus' analysis, Avicanna stock appears to be undervalued.
The current stock price of €0.08 is trading 48.7% below its estimated GF Value™ of €0.15.
Key valuation signals for FRA:0NN:
Debt-to-Equity: 0.04 (43% below median its 10-year median of 0.07)
GF Value™: €0.15 vs. price of €0.08 (48.7% below fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#122 of 813)
No single metric tells the full story. See the FRA:0NN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada.
50GF Score
Get the complete analysis for FRA:0NN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0NN has been successfully added to your 
